Virtual Reality Mindfulness for Migraine

(MIRAGE Trial)

This trial explores whether a virtual reality headset can help reduce the impact of migraines by teaching mindfulness techniques. It specifically examines Acceptance and Commitment Therapy (ACT) delivered through the REACT NeuroVR headset to determine if it can decrease migraine-related disability. Participants will either maintain their usual treatment or engage in the VR mindfulness therapy for four weeks, tracking their symptoms throughout. The trial seeks individuals who experience 4-10 migraine days per month and are already on stable migraine prevention medication. As an unphased trial, it offers a unique opportunity to explore innovative migraine management techniques using cutting-edge technology.

The trial requires that you are not taking any preventive medications other than a stable dose of CGRP mAb (a type of migraine medication) for three months before joining. If you are on other preventive medications, you may need to stop them.

Research has shown that Acceptance and Commitment Therapy (ACT), when combined with a virtual reality headset, is generally easy for patients to manage. Studies have found that ACT can reduce disability in adults with migraines, offering a helpful approach without major safety concerns. A review of studies on acceptance-based treatments, including ACT, found them effective and safe for people with migraines. Additionally, virtual reality (VR) has successfully taught mindfulness, a key component of ACT, to migraine patients without major side effects.

Researchers are excited about using ACT therapy delivered through the REACT NeuroVR headset for migraines because it combines mindfulness with cutting-edge virtual reality technology. Unlike typical treatments, which often involve medications like CGRP monoclonal antibodies, this approach immerses patients in a virtual environment to enhance relaxation and stress management. This novel delivery method could offer a drug-free complement to traditional therapies, potentially reducing the frequency and intensity of migraine attacks in a way that is engaging and accessible.

Research has shown that Acceptance and Commitment Therapy (ACT) can alleviate migraine symptoms and enhance overall life satisfaction. Studies have found that ACT improves emotional management and reduces the impact of migraines on daily life. In this trial, one group will engage in a four-week active virtual reality treatment using the REACT NeuroVR headset to deliver ACT, while continuing their CGRP mAb medication. Early results suggest that VR-based mindfulness therapy can effectively manage migraine issues. Combining mindfulness techniques with VR technology might provide a promising non-drug option for those suffering from migraines.¹²³⁵⁶